Skip to main content
KBS_Icon_questionmark link-ico

The PET Centre
Clinical services for patients and clinically related research

We are the leading clinical PET centre in the UK, currently receiving over 6000 patients a year, the vast majority of these being whole body FDG oncology studies.

Our work includes providing a clinical PET service for patients and performing basic, translational and applied clinical PET research across all specialities including oncology, neurology, psychiatry and cardiology.

The PET Centre is the first in the UK to have a purpose designed scanning suite with two state-of-the-art PET-CT scanners and a simultaneous PET-MR scanner. We also have a third PET-CT scanner in the Cancer Centre at Guy's Hospital.


Current Areas of Research

The Centre is active in many areas of research, including the development and evaluation of new tracers, the development and assessment of new clinical PET indications, coordination of national and international cancer trials using PET-CT imaging and new PET technology and data analysis methods.

  • Development and Evaluation of Novel PET-MR Acquisition and Reconstruction Techniques for Improved Diagnosis of Heart Disease

Tracers currently used in our neurology studies include: [18F]fallypride, [18F]florbetapir, [18F]florbetaben, [18F]DPA-714, [18F]GE-179.

  • Tracking myelin changes in vivo with 18F-florbetapen PET and MRI in patients with Multiple Sclerosis. A Proof of concept Pilot study
  • A phase III, randomized, placebo-controlled, parallel-group, double blind clinical trial to study the efficacy and safety of MK-8931 (SCH 900931) in subjects with amnestic Mild Cognitive Impairment due to Alzheimer's Disease (prodromal AD).
  • Investigating the role of glutamate and the N-methyl-D-aspartate-Receptor (NMDAR) in brain function
  • Investigating the effect of Continuous Positive Airway Pressure on the Neuropathology of Obstructive Sleep Apnoea (INCOSA)
  • Dopamine release and blood flow changes during induced epileptic seizures assessed with simultaneous PET-MR
  • The role of inflammation in brain and cognitive function in mental disorders (IRIS)
  • Evaluation of Brain PET/MR versus PET-CT

Tracers currently used in our oncology studies include: [18F]FDG, [18F]fluoride, [18F]choline, [18F]MISO, [68Ga]PSMA, [18F]fluciclovine.

  • A Phase 1 Study of LY3039478 in Patients with Advanced or Metastatic Cancer (NOTCH)
  • MRI assessment of hypoxia and perfusion in primary colorectal cancer: Correlation with imaging and immunohistochemical markers of hypoxia (MATCH)
  • METfomin And Longevity (METAL): A window of opportunity study investigating biological effects of metformin in localised prostate cancer
  • A phase 3, open-label study to assess the utility of Fluciclovine (18F) Injection PET/CT in patients with prostate cancer with biochemical recurrence after initial treatment - BED007
  • A randomized double-blind phase 3 study of avelumab in combination with standard of care chemoradiotherapy (cisplatin plus definitive radiation therapy) versus standard of care chemoradiotherapy in the front-line treatment of patients with locally advanced squamous cell carcinoma of the head and neck - JAVELIN
  • An open label, single arm pilot study of OncoSilTM, administered to study participants with unresectable locally advanced pancreatic adenocarcinoma, given in combination with FOLFIRINOX or gemcitabine+nab-paclitaxel chemotherapies - OncoSil PANCO
  • A pilot study of positron lymphography for pre-operative axillary nodal staging among breast cancer patients
  • A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) - SADAL
  • A Phase 1 Adaptive Dose-Escalation Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of ADCT-301 in Patients with Relapsed or Refractory Hodgkin Lymphoma and Non-Hodgkin Lymphoma ADCT-301-001A
  • Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - INCYTE HANK
  • TIDaL - Risk-stratified sequential Treatment with Ibrutinib and Rituximab (IR) and IR-CHOP for De-novo post-transplant Lymphoproliferative disorder (PTLD)
  • Histological correlation for textural features of PET & CT in NSCLC - FALCON
  • First international Inter-Group Study for nodular lymphocyte predominant Hodgkin`s Lymphoma in Children and Adolescents EuroNet-PHL-LP1
  • Functional Imaging for Response evaluation assessment in rectal cancer.
  • Evaluation of treatment response and resistance in metastatic renal cell cancer (mRCC) using integrated 18F-Fluorodeoxyglucose (18F-FDG) positron emission tomography/magneticresonance imaging (PET/MRI): The REMAP study
  • Response evaluation in myeloma patients using integrated 18F-Fluorodeoxyglucose (18F-FDG) positron emission tomography/magnetic resonance imaging (PET/MRI): The REVAMP study.
  • FABB: B A study using functional imaging biomarkers including 18F-fluoride PET, 18FDG PET and DW MRI to assess early treatment response in skeletal metastases from breast cancer.
  • FAB P - Functional Assessment of Bone metastases in Prostate cancer
  • Improving non-invasive diagnosis and characterisation of prostate cancer with PET/MRI - PROSPER
  • Histological correlation for textural features of PET &ceCT in NSCLC

  • An open-label, single centre, pilot study exploring the impact of switching to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) on regional bone turnover measured using 18F-PET in HIV-1-infected patients virologically suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF). PETRAM
  • A randomized, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, and effects on heterotopic bone formation of regn2477 in patients with fibrodysplasia ossificans progressiva - REGENERON FOP


Scanning and Tracer Production Facilities

Clinical and research scanning is carried out on two GE Discovery 710 PET-CT scanners, one Siemens Biograph mCT Flow PET-CT scanner and one Siemens Biograph mMR PET-MR scanner. Additional equipment includes various well counters and online sampling for complex quantitative dynamic studies, motion tracking devices, radiotherapy lasers and a comprehensive computer network for reporting, data analysis and archiving.

We also have an RDS 112 11.2 MeV cyclotron and radiochemistry laboratory with 6 hot-cells capable of producing a wide range of tracers for clinical and research studies. All tracers are produced to GMP standards.

Our Team



Through the work of our centre, we are developing exciting PET methodology such as PET-MR and performing critical research into radioactivity via our in-house cyclotron facilities and our multi-disciplinary expertise.

Professor Alexander Hammers Head of the PET Centre and Professor of Imaging and Neuroscience

Contact us

For any queries you might have, please don't hesitate to contact us.

020 7188 4988

Our partners

Pet Centre Partner Logos

The National PET Imaging Platform



The UK's first-of-its-kind national total-body PET imaging platform for drug discovery.